Anti Amyloid Leqembi denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for anti amyloid leqembi are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UHC Denied Leqembi as Experimental — and Why You Can Appeal

Leqembi (lecanemab) received traditional FDA approval for the treatment of early Alzheimer's disease with confirmed amyloid pathology. A denial on "experimental or investigational" grounds is factually inconsistent with the drug's regulatory status and is one of the most directly challengeable denial types for this therapy. Insurers sometimes apply this denial when their internal coverage policy has not been updated to reflect a drug's full approval, or when their policy imposes requirements beyond FDA approval that have not been met.

## Why This Denial Is Appealable

An "experimental" denial for an FDA-approved therapy used within its approved indication requires the insurer to articulate a specific, clinical basis — not simply assert that its internal policy predates the approval. Under ACA §2719 and ERISA §503, UHC must provide a full internal appeal and independent external review. The external review window under federal rules is approximately four months from exhaustion of internal appeals. For time-sensitive cases, expedited review (typically decided within 72 hours) is available. External reviewers — independent, board-certified specialists — are particularly likely to overturn experimental denials for fully approved therapies.

## What to Gather

• FDA approval documentation: Print the FDA drug approval letter and the current FDA prescribing information confirming traditional (not accelerated) approval status and the approved indication.
• Indication match: The prescriber must confirm in writing that the patient's use matches the FDA-approved indication (early Alzheimer's disease with amyloid confirmation).
• Amyloid confirmation records: PET scan or CSF biomarker results confirming amyloid positivity.
• Guideline support: A letter from the treating specialist citing the relevant neurology guideline organization's endorsement of anti-amyloid therapy for this indication, without quoting specific numeric thresholds.
• UHC policy version date: If UHC's policy predates the FDA full approval, document that discrepancy explicitly.

## Criteria-Mapping Approach

Obtain UHC's current coverage policy for Leqembi. List every criterion it applies to define "experimental" or "not medically accepted." Map the FDA approval status, the approved indication, and current guideline organization recommendations against each criterion. If the policy cites a date predating traditional approval, flag that directly. The appeal letter should open with the FDA approval status and build from there.